Hormone receptor-positive, HER2-negative breast cancer (HR+/HER2-BC) generally has a more favourable prognosis but still exhibits unpredictable progression and recurrence due to heterogeneity in the TME. The gene discussed is NR4A1; the disease is breast cancer.